Yazarlar : Dodero1, F Spina1, F Narni2, F Patriarca3, I Cavattoni4, F Benedetti5, F Ciceri6, D Baronciani7, R Scime`8, E Pogliani9,
Yayın : Leukemia (2012) 26, 520–526
Yayın Yılı : 2011
Pubmed Linki : www.nature.com/leu
Konu : Kemik İliği Nakli
Literatür İçeriği :
Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus lymphoma effect Rescue chemotherapy or autologous stem cell transplantation (autoSCT) gives disappointing results in relapsed peripheral T-cell lymphomas (PTCLs). We have retrospectively evaluated the long-term outcome of 52 patients receiving allogeneic SCT for relapsed disease. Histologies were PTCL-not-otherwise specified .
T-cell lymphomas (64%) or alternative donors (11%) from haploidentical family donors), following reducedintensity conditioning (RIC) regimens including thiotepa, fludarabine and cyclophosphamide. Most of the patients had chemosensitive disease (previous autoSCT. At a median follow-up of 67 months, 27 of 52 patients were found to be alive (52%) and 25 (48%) were dea(The cumulative incidence (CI) of NRM was 12% at 5 years. Extensive chronic graft-versus-host disease increased the ris of NRM (33% versus 8%, 5 years, influenced by disease status at the time of allograftic(survival and progression-free survival (PFS) were 50% (95% CI, 36 – 63%) and 40% (95% CI, 27 – 53%), respectively. The curren PFS was 44% (95% CI, 30–57%). In all, 8 out of 12 patients (66%) who received donor-lymphocytes infusions for disease progression had a response. At multivariable analysis, refractory disease and age over 45 years were independent adverse prognostic factors. RIC allogeneic SCT is an effective salvage treatment with a better outcome for younger patients with chemosensitive disease.
| Sunumlar | Videolar | Olgu Tartışması |
